Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Regulation Advisory Committees Drug Review

Recent And Upcoming FDA Advisory Committees

  • News

Executive Summary

Recent and upcoming FDA advisory committee meetings and a summary of topics covered.

You may also be interested in...



Sanofi-Pasteur's Southern Strategy Gets Its Own FDA Advisory Committee

Fluzone remains only flu vaccine on US market with an FDA-approved southern formulation.

Cempra's Solithromycin On Track To Enter Generic, But Resistant, CABP Market

FDA schedules November advisory committee for Cempra's first-in-class antibiotic for community-acquired bacterial pneumonia.

Podcast: Diversity, Equity, and Inclusion Measures Continue to Evolve in the Clinical Space

Listen to expert perspectives from Tracey Parker, Vice President, Biometrics, Advanced Clinical and Rebecca Starkie, Senior Global Patient Engagement Director, Advanced Clinical on the recent history of DEI in clinical trials and the barriers to patient participation. Examine the key drivers that have influenced the development of diversity, equity, and inclusion programs for clinical trials.

Table

View full table

Topics

Tags:
Regulation Advisory Committees Drug Review
Latest Headlines

AstraZeneca/Sanofi’s Nirsevimab Nears US FDA Approval After Overwhelmingly Positive Adcomm

FDA’s Office Of Generic Drugs Gets New Permanent Director And Oversight Designee

Big Drug, Small Panel: US FDA Adcomm For Eisai/Biogen’s Leqembi Includes Only Six Voting Members

US FDA Balances Urgent Need For Platinum Chemotherapies Against Intas Plant’s Quality Failures

See All
UsernamePublicRestriction

Register

PS119313

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By